RxDoctor Payments Data

Ravi Shridhar, PhD

Radiation Oncology · Orlando, FLNPI 1356565261

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $136,410 of the $192,071 with a category attached, or 71.0%. 26 manufacturers reported payments, led by Boston Scientific at 57.1% of the total. Reporting peaked in 2023 at $72,673 and has fallen 73.9% since, to $18,953 in 2025. Among radiation oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$192,071in general payments, 2019–2025

Across 299 payments — averaging $642.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$110K
  • AstraZeneca$46K
  • Histosonics, Inc.$21K
  • Novartis$4K
  • Siemens Medical Solutions USA, Inc.$3K
  • Delcath Systems$2K
  • plus $6K from 20 others
$119,914in research payments, 2019–2025

Across 17 payments — averaging $7053.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$115K
  • ABK Biomedical USA, Inc.$4K
  • Novartis Pharma AG$959

What the payments were for

  • Consulting fees$26,90514%
  • Speaking & faculty fees$136,41071%
  • Travel & lodging$16,4549%
  • Food & beverage$12,3026%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,071 in reported general payments places this provider in the 95th percentile of 465 radiation oncology providers in Florida.

See all radiation oncology providers in Florida

Medicare billing

Part B allowed, 2024
$272,242
Medicare patients
332
Services billed
2,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl23$1,479
Sucralfate42$1,396
Tamsulosin Hcl51$670
Ondansetron Hcl12$413
Methylprednisolone49$400
Prednisone63$355
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$291
Ondansetron OdtOndansetron12$257
Oxycodone Hcl18$216
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$214
SsdSilver Sulfadiazine11$147

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →